Journal article
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.
Sanjay Popat, Benjamin J Solomon, Tom Stinchcombe, Geoffrey Liu, Gilberto Lopes, Melissa Lynne Johnson, Misako Nagasaka, Ece Cali Daylan, Christina S Baik, James Thomas D'Olimpio, Tzu-chuan Jane Huang, Alexander I Spira, Daniel Ernest Haggstrom, Ben C Creelan, Kristina Kehrig, Junwu Shen, Rachel DeLaRosa, Viola Weijia Zhu, Alexander E Drilon, Alice Tsang Shaw
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2025
Abstract
TPS8666 Background: Oncogenic ALK gene fusions are detected in ~5% of advanced non-small cell lung cancer (NSCLC) cases. Among these patients, the incidence of brain metastases at diagnosis is ~40%. Prior generations of ALK tyrosine kinase inhibitors (TKIs) present limitations that may influence efficacy and tolerability, such as inadequate control of brain metastases, treatment-emergent drug-resistant ALK mutations, or off-target adverse events, particularly neurological events associated with inhibition of the structurally related TRK kinases. Neladalkib is a potent, brain-penetrant, ALK-selective..
View full abstract